Charles River Laboratories International Inc
Q2 2026 Earnings
Market Reaction
Did CRL Beat Earnings? Q2 2026 Results
Charles River Laboratories delivered a stronger-than-expected second quarter, posting non-GAAP diluted EPS of $3.02 against the $2.73 consensus estimate, a 10.65% beat that marked the company's fifth consecutive quarter of exceeding EPS expectations. Revenue of $1.00 billion topped the $977.20 million consensus by 2.75%, though it declined 2.7% year-over-year, a drop largely attributable to the completed divestitures of the CDMO and Cell Solutions businesses rather than underlying demand erosion. The more telling signal came from the DSA segment, where the net book-to-bill ratio reached its highest level in nearly four years, with demand improvement described as broad-based across both large biopharmaceutical and small-to-mid-sized biotech clients. That momentum gave management enough confidence to raise full-year guidance, lifting organic revenue growth expectations to 0.0%-1.0% and increasing non-GAAP EPS guidance to $11.15-$11.45, a $0.25 midpoint improvement, even as GAAP EPS guidance was trimmed to $3.05-$3.35 to reflect divestiture-related losses recorded in the quarter.
- DSA segment recorded highest net book-to-bill in nearly four years with broad-based improvement across global biopharmaceutical and small/mid-sized biotech clients
- Organic revenue growth of 0.1% was the highest since Q3 2023
- Manufacturing segment organic revenue increased 1.3% driven by higher Microbial Solutions revenue
- Non-GAAP operating margin increased 420 basis points sequentially to 20.5%
- Deferred compensation plan investment gains provided $0.19 per share benefit
“We made excellent progress in the second quarter on the execution of our Pathway to Purpose strategy. We are actively evaluating opportunities to modernize the Company and drive greater efficiency, to strengthen our leading drug development portfolio centered on regulated testing, and to further enhance our growth profile. We are focused on continuing to move forward on achieving our strategic initiatives and financial goals, which will strengthen our foundation and underpin our future success.”
Charles River Laboratories CEO, on the earnings call
Forward Guidance & Outlook
Charles River raised its 2026 guidance. Reported revenue growth is now expected at (3.5)% to (2.5)%, with organic revenue growth of 0.0% to 1.0% (up 150 basis points at midpoint). Non-GAAP EPS guidance increased to $11.15–$11.45 (up $0.25 at midpoint), primarily driven by improving demand trends in the DSA segment and better-than-expected Manufacturing segment performance. GAAP EPS guidance was lowered to $3.05–$3.35 due to the net loss on divestitures. The company expects Q2 deferred compensation plan investment gains to be largely offset by a higher tax rate for the full year, with negligible net impact to non-GAAP EPS.
CRL YoY Financials
CRL Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.